Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-4199 CR in Bipolar I Depression
NCT05169710Phase 3Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of SEP-4199 in bipolar I disorder, sponsored by Sumitomo Pharma America. Started Dec 2021; status: terminated.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT05169710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169710.